More than 38 million Americans suffer from migraine. It is the sixth most disabling neurologic disease globally, according to the World Health Organization.
Yet, migraine often is undiagnosed and left untreated. Dr. Amaal Starling, a neurologist at Mayo Clinic, says because the neurologic disease is so incapacitating, it is important to have a variety of treatment options. Dr. Starling is the lead author of a new study that looked at single pulse transcranial magnetic stimulation for the preventive treatment of migraine.
A migraine. It’s much more than a headache. And it can be debilitating.
“It’s a neurologic disease that has light sensitivity, sound sensitivity, motion sensitivity, nausea, vomiting. There are so many components,” says Dr. Starling.
There is no cure for migraine but there is a new option cleared by the U.S. Food and Drug Administration for the acute and preventive treatment of migraine.
“The device is called a single-pulse transcranial magnetic stimulation device,” says Dr. Starling.
She says the device transmits a signal to the brain, reducing brain hyperexcitability.
“Place it on the back of the head just like that [beeping]’ and then you push these two buttons,” says Dr. Starling. “And that administers a pulse.”
The first step, says Dr. Starling, is to get people with migraine to their health care provider so they can be properly diagnosed and treated.
The Latest on: Migraine
via Google News
The Latest on: Migraine
BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab
on April 18, 2018 at 9:47 am
April 18 (Reuters) - Alder Biopharmaceuticals Inc: * ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage: Our ... […]
New drug halves previously untreatable migraine attacks
on April 18, 2018 at 8:06 am
A new drug offers fresh hope to the millions of people living with treatment-resistant migraine. The compound, called erenumab, has proven successful in people who had been failed by up to four previous preventative treatments. The new study was led by Dr ... […]
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
on April 18, 2018 at 6:52 am
Amgen Inc. AMGN has announced full results from the phase IIIb study on its anti-CGRP receptor antibody, Aimovig (erenumab), which once again demonstrates a significant reduction in migraine frequency. The company is looking to get Aimovig (140mg) approved ... […]
Pharmalittle: Amgen migraine drug show promise; DEA moves to tighten opioid rules
on April 18, 2018 at 6:51 am
ood morning, everyone, and how are you today? The middle of the week is here, which means your survival skills are intact — so far. To celebrate, and to stay on track, you may want to reach for a cup of stimulation. We have already enjoyed a mug of ... […]
New Migraine Treatment Could Provide Relief Without Side Effects
on April 17, 2018 at 9:09 pm
A drug known as erenumab may be able to help sufferers of hard-to-treat migraines, researchers have found. The preliminary study on the new treatment was released on April 17 and will be presented at the American Academy of Neurology's 70th Annual Meeting ... […]
Migraine: New drug works when others fail, researchers say
on April 17, 2018 at 2:27 pm
These are external links and will open in a new window A new migraine medication - one of the first bespoke drugs for decades - appears to work well even when others have failed, researchers have said . Erenumab is a monthly injection that might soon be ... […]
New migraine treatment could help when other drugs fail
on April 17, 2018 at 2:19 pm
A new drug could help those suffering from the most hard-to-treat migraines. Research on patients who had been treated unsuccessfully with other medications found that the new treatment halved the number of episodes among some patients. Overall, 30 per ... […]
Migraine sidelines Byron Buxton for Twins-Indians game in Puerto Rico
on April 17, 2018 at 1:47 pm
Byron Buxton was scratched from the Twins lineup Tuesday night because of a migraine. Greetings from San Juan, Puerto Rico ... where the Twins and Indians begin a two-game series at Estadio Hiram Bithorn. It was pouring at the stadium at 4 p.m. local time ... […]
Amgen's Aimovig halved migraine days in 30 percent of trial patients
on April 17, 2018 at 1:17 pm
LOS ANGELES (Reuters) - A late-stage trial of Amgen Inc’s experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients ... […]
via Bing News